PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33821268-6	2021	The mechanism of the protease inhibitors nafamostat and camostat extend beyond inhibition of TMPRSS2 to coagulation-induced spike cleavage.	nafamostat	41-51	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	124-129	
32532094-3	2020	Here we established a quantitative fusion assay dependent on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein, angiotensin I converting enzyme 2 (ACE2) and TMPRSS2, and found that nafamostat mesylate potently inhibited the fusion while camostat mesylate was about 10-fold less active.	nafamostat	202-221	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	110-111	
32532094-6	2020	Together, our study shows that nafamostat mesylate potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and also inhibits SARS-CoV-2 infection in vitro in a cell-type-dependent manner.	nafamostat	31-50	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	69-70	
34541574-2	2021	Here, we evaluate nafamostat mesylate, a potent broad-spectrum serine protease inhibitor that blocks host protease activation of the viral spike protein.	nafamostat	18-37	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	139-144	
35294338-7	2022	The mechanism of the protease inhibitors nafamostat and camostat may extend beyond inhibition of TMPRSS2 to coagulation-induced spike cleavage.	nafamostat	41-51	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	128-133